Toggle Menu

Press Room

Phase 2 clinical trial on volitinib in papillary renal cell carcinoma


At the Thirteenth International Kidney Cancer Symposium, Dr Toni Choueiri (Dana-Farber Cancer Institute and Harvard Medical School, MA) discusses the new AstraZeneca-sponsored Phase 2 clinical trial on the c-Met inhibitor, volitinib, in patients with papillary renal cell carcinoma (pRCC).

NeonCRM by Neon One